Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer
June 29 2021 - 9:00AM
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision
oncology company developing next-generation therapies that target
genetic drivers of cancer, today named Paolo Tombesi as executive
vice president and CFO, effective July 26. Mr. Tombesi brings 30
years of global financial and accounting experience to Turning
Point from multiple prior financial leadership roles within biotech
and pharmaceutical companies, most recently serving as CFO of
Epizyme, Inc.
“Paolo brings very valuable global financial experience to our
growing team, particularly in supporting commercial organizations
and product launches,” said Athena Countouriotis, M.D., president
and CEO. “As we build our finance organization and prepare for the
potential launch of repotrectinib, we are pleased to have a veteran
financial leader of Paolo’s caliber joining our team.”
As CFO of Epizyme, Mr. Tombesi supported the commercial launch
of Tazverik (tazemetostat) for the treatment of relapsed or
refractory follicular lymphoma, and was responsible for capital
funding, treasury, tax and accounting, SEC reporting, financial
planning and analysis, and procurement. Prior to Epizyme, he was
CFO for Insmed, Inc., where he led financial operations and
preparation for the commercial launch of Arikayce (amikacin
liposome inhalation suspension). From 2006 to 2014, he served in
roles of increasing responsibility for Novartis, including chief
financial and administrative officer of Novartis Pharmaceuticals
Corporation; managing director and CFO of Novartis Japan; and CFO
of the European Oncology division. Earlier in his career, he served
in financial roles for Bristol Myers Squibb in the U.S. and Europe,
and Unilever and Johnson & Johnson in Italy.
“I am excited to join the Turning Point team at such an
important point in the company’s evolution, with four clinical
stage assets in development and as the company prepares for
potential commercialization,” said Mr. Tombesi. “I am so impressed
with Athena, the Turning Point leadership team and its board of
directors and look forward to supporting the company’s continued
growth.”
About Turning Point Therapeutics Inc.Turning
Point Therapeutics is a clinical-stage precision oncology
company with a pipeline of internally discovered investigational
drugs designed to address key limitations of existing cancer
therapies. The company’s lead drug candidate, repotrectinib, is a
next-generation kinase inhibitor targeting the ROS1 and TRK
oncogenic drivers of non-small cell lung cancer and advanced solid
tumors. Repotrectinib, which is being studied in a registrational
Phase 2 study in adults and a Phase 1/2 study in pediatric
patients, has shown antitumor activity and durable responses among
kinase inhibitor treatment-naïve and pre-treated patients. The
company’s pipeline of drug candidates also includes TPX-0022,
targeting MET, CSF1R and SRC, which is being studied in a Phase 1
trial of patients with advanced or metastatic solid tumors
harboring genetic alterations in MET; TPX-0046, targeting RET,
which is being studied in a Phase 1/2 trial of patients with
advanced or metastatic solid tumors harboring genetic alterations
in RET; and TPX-0131, a next-generation ALK inhibitor, which is
being studied in a Phase 1/2 trial of previously treated patients
with ALK-positive advanced or metastatic non-small cell lung
cancer. Turning Point’s next-generation kinase inhibitors are
designed to bind to their targets with greater precision and
affinity than existing therapies, with a novel, compact structure
that has demonstrated an ability to potentially overcome treatment
resistance common with other kinase inhibitors. The company is
driven to develop therapies that mark a turning point for patients
in their cancer treatment. For more information, visit
www.tptherapeutics.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as “plans”, “will”,
“believes,” “anticipates,” “expects,” “intends,” “goal,”
“potential” and similar expressions are intended to identify
forward-looking statements. Such forward-looking statements include
statements regarding the potential launch and commercialization of
repotrectinib and Turning Point Therapeutics’ continued growth.
These forward-looking statements are based upon Turning Point
Therapeutics’ current expectations and involve assumptions that may
never materialize or may prove to be incorrect. Actual results
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with Turning Point Therapeutics’ business
in general, risks and uncertainties related to the impact of the
COVID-19 pandemic to Turning Point’s business and the other risks
described in Turning Point Therapeutics’ filings with the SEC,
including its quarterly report on Form 10-Q filed with the SEC on
May 5, 2021. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Turning
Point Therapeutics undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Contact: Jim
Mazzolajim.mazzola@tptherapeutics.com858-342-8272
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Apr 2024 to May 2024
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From May 2023 to May 2024